A real-world analysis of FDA Adverse Event Reporting System (FAERS) events for liposomal and conventional doxorubicins

Nature·Mar 1

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

A study has analyzed adverse event reports for liposomal and conventional doxorubicins using the FDA Adverse Event Reporting System. The context of this analysis is not entirely clear, as reports from various outlets mention different topics, including vaccine adverse events, cancer drugs, and pharmacovigilance studies. It appears that multiple studies are utilizing the FDA Adverse Event Reporting System to examine various medications and their potential adverse effects.

Full coverage

Evaluating the Evolving Real-World Adverse Events of GLP-1RAs Using FDA Adverse Event Reporting System (FAERS)

Wiley Online Library·Mar 9

Factors associated with serious adverse event following immunization: a real-world analysis of the vaccine adverse event reporting system 2025

Frontiers·Apr 14

Early Evaluation of the Food and Drug Administration (FDA) Adverse Event Monitoring System (AEMS): An Analysis of Over 32 Million Pharmacovigilance Reports

Cureus·Apr 1

Drug-induced vanishing bile duct syndrome: A real world pharmacovigilance study using the FDA adverse event reporting system

Springer Nature Link·Feb 20

Cancer Drugs Erdafitinib, Pemigatinib Cause Dry Eye

Review of Optometry·Jun 2

Cutaneous adverse reactions associated with enfortumab vedotin: a pharmacovigilance study based on the FDA adverse event reporting system

Frontiers·Mar 16

Ovarian Cancer Drugs May Raise Risk of Lung Disease

Docwire News·Feb 19

Pharmacovigilance Analysis of Bleeding Events Associated With Selective Serotonin Reuptake Inhibitors (SSRIs) Using the US Food and Drug Administration Adverse Event Reporting System (FAERS)

Cureus·Jun 3

View original report at Nature ↗

Fetching the latest headlines…